The results showed that BCR/ABL-T315I CML patients displayed hallmark of IL2 STAT5, IL6 JAK STAT3 signaling, P53 pathway and KRAS signaling. This evidence concerns the gene IL2 and chronic myelogenous leukemia, BCR-ABL1 positive.